Figure 1.
(A) Schematic illustration of aberrant and potentially druggable signalling in leukemic blasts leading to cellular proliferation and survival advantage in acute myeloid leukemia (AML). (B) Targets of new AML treatment agents inhibiting/blocking impaired cellular pathways and inducing leukemia cell death.